Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

66.16USD
23 Jun 2017
Change (% chg)

$0.14 (+0.21%)
Prev Close
$66.02
Open
$65.86
Day's High
$66.38
Day's Low
$65.85
Volume
6,209,808
Avg. Vol
3,054,678
52-wk High
$66.80
52-wk Low
$55.10

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $180,958.50
Shares Outstanding(Mil.): 2,735.17
Dividend: 0.47
Yield (%): 2.84

Financials

  MRK.N Industry Sector
P/E (TTM): 42.39 14.09 19.01
EPS (TTM): 1.56 -- --
ROI: 5.54 -6.73 -5.03
ROE: 10.39 -6.18 -4.28

Gilead knocks out Merck patent on hepatitis C treatment

An appeals court handed biopharmaceutical company Gilead Sciences Inc a victory on Tuesday in its litigation with Merck & Co Inc over the blockbuster hepatitis C drug Sovaldi.

Jun 21 2017

BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study

* Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)

Jun 21 2017

BRIEF-Leap Therapeutics announces collaboration with Merck

* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer

Jun 21 2017

BRIEF-PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications

* Is entering a cooperation with Merck to develop technology applications for single-crystalline metal particles Source text for Eikon: Further company coverage:

Jun 20 2017

BRIEF-Serimmune announces research, development collaboration agreement with subsidiary of Merck

* Announced a research and development collaboration agreement with a subsidiary of Merck

Jun 20 2017

BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma

* Human longevity - signed agreement with merck kgaa, darmstadt, germany which operates its biopharmaceutical business as emd serono in u.s. And canada

Jun 15 2017

Merck to pause two late-stage studies testing Keytruda in myeloma

Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug, Keytruda, for multiple myeloma, in combination with other therapies, as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups.

Jun 12 2017

UPDATE 1-Merck to pause two late-stage studies testing Keytruda in myeloma

June 12 Merck & Co said it paused enrolments in two late-stage studies testing its immunotherapy drug, Keytruda, for multiple myeloma, in combination with other therapies, as the U.S. drugmaker looks to better understand more reports of death in the Keytruda groups.

Jun 12 2017

CORRECTED-Merck to pause two late-stage studies testing Keytruda in myeloma

June 12 Merck & Co said on Monday it paused enrolments in two late-stage studies testing its immunotherapy drug Keytruda used in combination with other therapies to treat multiple myeloma, a type of blood cancer.

Jun 12 2017

BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies

* Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda® (pembrolizumab) in combination with other therapies

Jun 12 2017

More From Around the Web

Competitors

Earnings vs. Estimates